Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 6/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8898242 | 0.99 | F7 (0.45) | F7F2PTPN11MAPKAPK2F10 | |
| SCHEMBL8899533 | 0.87 | F7 (0.46) | F7F2F10CA12CA1 | |
| SCHEMBL8896780 | 0.87 | F7 (0.41) | F7F2PTPN11MAPKAPK2F10 | |
| SCHEMBL4417206 | 0.86 | PPID (0.47) | F7CTSKCA12CA1CA2 | |
| SCHEMBL8382918 | 0.84 | ATM (0.48) | CTSKCA1CA2CA9HDAC1 | |
| SCHEMBL27523391 | 0.78 | PRMT1 (0.45) | F2ALDH1A1 | |
| SCHEMBL13993073 | 0.78 | POLB (0.36) | PTPN11CTSKHDAC1 | |
| SCHEMBL8898015 | 0.78 | F7 (0.47) | F7F2 | |
| SCHEMBL27994504 | 0.76 | SMN1; SMN2 (0.50) | ALDH1A1 | |
| SCHEMBL617014 | 0.76 | MAPT (0.52) | CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-05-02 | — | — | US | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | F7, F9, F5 | F7 1/4885F2 15/4885PTPN11 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.